Skip to main content


Figure 1 | BMC Cancer

Figure 1

From: Hsp90 inhibition differentially destabilises MAP kinase and TGF-beta signalling components in cancer cells revealed by kinase-targeted chemoproteomics

Figure 1

Changes in kinase abundance upon geldanamycin treatment. Relative quantification of kinases identified from Hs68, SW480, U2OS and A549 cells treated with geldanamycin for 24 h following enrichment on Kinobeads (from two independent experiments). Fold change refers to the ratio between geldanamycin-treated and DMSO-treated cells. a) Heat map representation of the effect of Hsp90 inhibition on the level of the 144 quantified kinases (log2 scale). Kinases are grouped in classes according to structural similarity of their catalytic domain. b) List of putative new Hsp90 kinase clients identified. Kinases were selected as client candidates if their log2 ratio (fold change treated versus untreated cells) is greater than-0.5 in Hs68 cells or in at least two cancer cell lines. The results are compared to literature data for evidence of previous associations (Additional file 5).

Back to article page